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NA topoisomerase (topo) II catalyses topological
genomic changes essential for many DNA metabolic
processes. It is also regarded as a structural com-
ponent of the nuclear matrix in interphase and the mitotic
chromosome scaffold. Mammals have two isoforms (
 
 
 
 and
 
 
 
) with similar properties in vitro
 
.
 
 Here, we investigated
their properties in living and proliferating cells, stably
expressing bioﬂuorescent chimera of the human isozymes.
Topo II
 
 
 
 and II
 
 
 
 behaved similarly in interphase but differently
in mitosis, where only topo II
 
 
 
 was chromosome associated
to a major part. During interphase, both isozymes joined in
nucleolar reassembly and accumulated in nucleoli, which
seemed not to involve catalytic DNA turnover because
D
 
treatment with teniposide (stabilizing covalent catalytic
DNA intermediates of topo II) relocated the bulk of the
enzymes from the nucleoli to nucleoplasmic granules.
Photobleaching revealed that the entire complement of
both isozymes was completely mobile and free to exchange
between nuclear subcompartments in interphase. In
chromosomes, topo II
 
 
 
 was also completely mobile and
had a uniform distribution. However, hypotonic cell lysis
triggered an axial pattern. These observations suggest that
topo II is not an immobile, structural component of the
chromosomal scaffold or the interphase karyoskeleton, but
rather a dynamic interaction partner of such structures.
 
Introduction
 
Type II topoisomerases are enzymes able to relax, (un)knot,
and (de)catenate closed circular DNA in vitro, properties
required for DNA replication, chromosome condensation,
and the segregation of daughter chromatids (Wang, 1996).
DNA topoisomerase (topo)* II was previously recognized as
the major nonhistone protein component of the chromo-
some scaffold (Earnshaw et al., 1985; Gasser et al., 1986)
and the interphase nuclear matrix (Berrios et al., 1985), in-
soluble nuclear structures believed to play an architectural
role. In keeping with this, topo II was detected by immuno-
cytochemistry along the longitudinal axes of gently expanded
chromosomes (Earnshaw and Heck, 1985; Gasser et al.,
1986) and shown to bind preferentially to AT-rich DNA el-
ements believed to specify the bases of chromatin loops
(Adachi et al., 1989). As a result, topo II is considered to
play a structural role in chromosome organization in addi-
tion to its enzymatic functions (Adachi et al., 1991). How-
ever, this view is not undisputed (Hirano and Mitchison,
1993), and lately the existence of a nuclear matrix in the living
cell nucleus has been questioned altogether (Pederson,
2000).
Another open issue regards the biological roles of the two
isoforms of mammalian topo II (
 
 
 
 and 
 
 
 
), which are similar
in primary structure, have almost identical catalytic proper-
ties in vitro (Austin and Marsh, 1998), and are both able to
complement topo II function in 
 
 
 
Top2
 
 strains of 
 
Saccharomyces
cerevisiae
 
 (Jensen et al., 1996a). In particular, the latter ob-
servation has argued against isoform-specific biological
functions of topo II
 
 
 
 and II
 
 
 
. However, this might not be
conclusive because yeast has only one form of topo II and
might not utilize the mammalian enzymes in an isoform-
specific manner.
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Research on functions of mammalian topo II isoforms in
their native environment has been impeded by various ob-
stacles. For example, it has not been possible to unambigu-
ously clarify their subnuclear localization. It has been estab-
lished that topo II
 
 
 
 binds to condensed chromosomes and
accumulates at centromeres in metaphase (Rattner et al.,
Figure 1. Characterization of HEK 293 
cells expressing topo II–GFP. (A) Western 
analysis of untransfected 293 cells and 
cells expressing GFP, topo II –GFP, or 
topo II –GFP. Blots were probed with GFP 
antibodies (top), or antibodies against 
human topo II  or II  (middle panels), or 
antibodies against  -tubulin serving as 
loading control (bottom). Arrowheads on 
the right margin indicate positions of topo 
II–GFP chimera. (B) DNA decatenation 
activity of GFP-fused and endogenous 
topo II. GFP-directed immunoprecipitates 
from cells expressing topo II –GFP or topo 
II –GFP and immunoprecipitates from 
untransfected cells directed at topo II  or 
II  were subjected to serial dilution and 
assessed for kDNA decatenation. SDS-
PAGE of the immunoprecipitates is shown 
four times in the inserts with arrowheads 
identifying those lanes that correspond to 
the respective decatenation assay. (C) 
Topo II immunoband depletion assay. The 
same cell lines as in Fig. 1 A were cultured 
1 h in medium containing 200  M tenipo-
side (  VM 26) or in plain medium (  VM 
26). Cells were then lysed, subjected to 
Western blotting, and the blots were 
probed with GFP-antibodies (top). The 
position of topo II–GFP is indicated on the 
right margin by an arrowhead. (D) Yeast 
complementation assay. The S. cerevisiae 
strain BJ201 carrying a disrupted endoge-
nous TOP2 gene which is substituted by 
the S. pombe Top2 gene on a URA3-
based plasmid, was transformed with 
LEU2 plasmids carrying either the TPI-pro-
moter alone ( ) or TPI-promoted topo II 
cDNAs encoding topo II , topo II -GFP, 
topo II , and topo II –GFP, respectively. 
After growth on selective plates (without 
Leu), single clones were streaked on plates 
with 5-FOA (right) to select for clones that 
had lost the S. pombe topo II–expressing 
plasmid. Plates without 5-FOA served as a 
control (left). Mitotic growth of cells trans-
formed with the topo II expression plas-
mids on 5-FOA plates indicates that the es-
sential topo II activity is likewise provided 
by GFP-tagged and untagged versions of 
human topo II isoforms. (E) Colocalization 
of GFP fusion proteins with endogenous 
topo II  and II  by indirect immunofluo-
rescence microscopy. Untransfected 293 
cells (top) and topo II - (bottom, left) or 
topo II –GFP-expressing cells (bottom, 
right) were grown on microscopic slides, 
PFA-fixed, permeabilized, and double 
stained with isoform-specific topo II anti-
bodies (columns II  and  , respectively) 
and DAPI. Corresponding images of phase 
contrast (Phase) and green fluorescence 
(GFP) are shown. From each staining com-
bination one representative cell in inter-
phase (top image) and pro-/metaphase 
(bottom image) is shown. 
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1996; Sumner, 1996), but it is unclear whether the enzyme
is distributed in the chromosome arms in a uniform (Boy de
la Tour and Laemmli, 1988) or axial manner (Earnshaw and
Heck, 1985; Gasser et al., 1986; Taagepera et al., 1993; Sai-
toh and Laemmli, 1994; Rattner et al., 1996; Sumner,
1996). The mitotic localization of topo II
 
 
 
 is even less clear.
Several investigations indicate that it is cytoplasmic during
cell division (Petrov et al., 1993; Chaly et al., 1996; Meyer
et al., 1997), whereas others also describe its association with
chromosomes (Taagepera et al., 1993; Sugimoto et al.,
1998). All of these studies were restricted to fixed or frac-
tionated specimen, and the disparate results have in part
been blamed on the use of different staining techniques and
antibodies (Chaly and Brown, 1996; Warburton and Earn-
shaw, 1997; Austin and Marsh, 1998). The most compre-
hensive study on topo II in living cells is based on micro-
injection of purified, fluorescently tagged topo II from
 
Drosophila melanogaster
 
 into living embryos, and has re-
vealed a dynamic but homogenous chromosomal distribu-
tion of the enzyme (Swedlow et al., 1993). Comparable in
vivo studies of the mammalian topo II isoforms using stable
heterologous expression of GFP chimera are missing, proba-
bly because overexpression of topo II
 
 
 
 induces apoptotic cell
death (McPherson and Goldenberg, 1998). On the other
hand, transient expression of topo II
 
 
 
 fused to the green flu-
orescent protein (GFP) has not yielded conclusive data from
cells in interphase, although it allowed confirmation of the
enzyme’s association with mitotic chromosomes (Mo and
Beck, 1999). Reports on the disposition of topo II
 
 
 
 in living
cells are not available.
Here, we achieved constitutive expression of active GFP
chimera of human topo II at physiological levels by a bal-
anced coexpression with a selection marker from bicistronic
transcripts. Thus, we could monitor dynamic relocations of
both isozymes during mitosis and assess their localization
and mobility during the whole cell cycle. Our data are suited
to address most of the issues summarized above.
 
Results
 
Constitutive expression of active topo II–GFP chimera 
in 293 cells
 
To avoid the deleterious effects of topo II overexpression
(McPherson and Goldenberg, 1998), we used a vector, al-
lowing a balanced expression of a selection marker and a sec-
ond (potentially harmful) protein via transcription of bicis-
tronic mRNA (Mielke et al., 2000). We transfected human
embryonal 293 kidney cells with such constructs, bearing in
the first cistron hybrid genes of topo II
 
 
 
 or II
 
 
 
 fused at their
C termini to GFP, and in the second cistron the selection
marker puromycin-
 
N
 
-acetyltransferase. Significantly less
puromycin-resistant cell clones emerged from transfection
with topo II–GFP than from transfection with the GFP
gene alone, attesting to a narrow tolerance margin for trans-
genic expression of topo II. However, cell lines supporting
constitutive expression of topo II
 
 
 
–GFP or topo II
 
 
 
–GFP
had growth rates and morphologies similar to untransfected
cells or cells expressing GFP alone. This suggested a quasi
physiological expression of the GFP-tagged topo II species
suitable for fluorescence studies in living cells, provided that
the fusion proteins were active, not overexpressed, and colo-
calized with their endogenous counterparts. Control experi-
ments addressing these issues are summarized in Fig. 1.
We performed Western blot analyses of the cell lines ex-
pressing topo II
 
 
 
–GFP (Fig. 1 A, lane 3) and topo II
 
 
 
–GFP
(Fig. 1 A, lane 4). Untransfected cells (Fig. 1 A, lane 1) and
GFP-expressing cells (Fig. 1 A, lane 2) served as controls. To
assess the integrity of the fusion proteins and to compare
their relative expression levels, the blots were probed with
GFP antibodies (Fig. 1 A, top panel). In transfected cells
(Fig. 1 A, lanes 3 and 4), chimeric topo II
 
 
 
 and II
 
 
 
 were de-
tected as single protein bands of the expected size (arrow),
but were absent in untransfected cells (Fig. 1 A, lane 1) and
in cells expressing GFP alone (Fig. 1 A, lane 2). Thus, we
could exclude rearrangements of the chimeric genes and as-
certain that green fluorescence of the cells was due to full-
length topo II–GFP chimera. Topo II
 
 
 
–GFP and topo II
 
 
 
–
GFP appeared to be expressed in similar amounts (Fig. 1 A,
compare lanes 3 and 4), allowing a comparison of data be-
tween these cell lines.
To compare expression levels of GFP-fused topo II
isozymes with the endogenous enzymes, blots were probed
with isoform-specific antibodies against topo II
 
 
 
 (Fig. 1 A,
second panel) or 
 
 
 
 (Fig. 1 A, third panel). The GFP chimera
could clearly be discriminated from the corresponding endog-
enous enzymes as additional bands of slower migration (Fig. 1
A, arrows). From comparison within each lane, it became evi-
dent that they were expressed at much lower levels than the
endogenous proteins. Moreover, the levels of untagged topo
II
 
 
 
 and II
 
 
 
 were the same in transfected and untransfected
cells, indicating that the additional expression of GFP-tagged
enzymes did not alter endogenous topo II expression.
Because protein functions could be disrupted by fusion to
GFP, we wanted to ascertain that the topo II–GFP chimera
Figure 2. Distribution of topo II–GFP in interphase nuclei. Phase-
contrast images and corresponding green fluorescence of living 293 
cells expressing topo II –GFP (left) and topo II –GFP (right). The 
insert shows images of selected nucleoli subjected to twofold 
magnification and contrast enhancement. Arrowheads indicate 
areas of decreased fluorescence intensity within the nucleoli. 
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had the same activity as the endogenous enzymes. We ad-
dressed this question by quantitative comparisons of the
DNA decatenation activities of endogenous and GFP-fused
enzymes isolated by immunoprecipitation. GFP-directed
immunoprecipitates from cells expressing GFP chimera con-
tained GFP-fused and unfused topo II in equal proportions
(Fig. 1 B, inserts, lanes 2 and 4), suggesting heterodimers of
GFP-fused and endogenous topo II. Upon comparing the
DNA-decatenation activity of these mostly heterodimeric
immunoprecipitates with similar amounts of endogenous
enzymes obtained from untransfected 293 cells by topo II–
directed immunoprecipitation (Fig. 1 B, inserts, lane 1 and
2, respectively), it appeared that the GFP chimera of topo
II
 
 
 
 (Fig. 1 B, second panel) and 
 
 
 
 (Fig. 1 B, bottom) had
the same activity as their endogenous counterparts (Fig. 1 B,
top and third panel, respectively), and could likewise be in-
hibited by the ATPase-inhibitor orthovanadate (Fig. 1 B,
outmost lanes on the right). Thus, fusion to GFP did not al-
ter the catalytic properties of the enzymes. In addition, to as-
certain that the GFP-fused enzymes were also active in the
cells, we employed immunoband depletion (Fig. 1 C),
which is based on the fact that the transient, covalent com-
Figure 3. Time-lapse imaging of topo II isoforms during mitosis. Cells expressing either topo II –GFP (left) or topo II –GFP (right) were 
grown on the microscope stage at 37 C and imaged at subsequent time points as indicated. Phase-contrast images and corresponding 
green fluorescence of representative cells are shown during progression from metaphase to early G1-phase. Video 1 (available at http://
www.jcb.org/cgi/content/full/jcb.200112023/DC1) shows topo II–GFP-expressing cells proceeding from prophase to early G1-phase. This 
image series represents a single optical section captured on a confocal microscope at intervals of 30 s. 
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plex between topo II and genomic DNA is stabilized by spe-
cific topo II poisons (Liu, 1989). As a consequence, topo II–
specific signals are depleted in Western analyses due to a
retention of topo II–DNA complexes in the gel slots. Un-
transfected and transfected 293 cells were treated with the
topo II poison teniposide (VM 26), and subjected to immu-
noblotting using GFP antibodies (Fig. 1 C, top). Obviously,
the treatment depleted topo II–fused GFP bands from the
blots (Fig. 1 C, compare lanes 5 and 6, and lanes 7 and 8).
The extent of depletion was similar to that of endogenous
topo II (unpublished data). GFP alone or 
 
 
 
-tubulin (Fig. 1
C, compare lanes 3 and 4, top and bottom, respectively)
were not depleted by VM 26, attesting to the specificity of
the assay. These results confirmed that topo II–GFP chi-
mera were as active as endogenous topo II because they
formed the same amount of catalytic intermediates in the ge-
nome of the transfected cells.
To judge the global functionality of topo II–GFP in com-
plex cellular processes such as mitosis, we tested complemen-
tation of topo II function in 
 
S. cerevisiae
 
 topo II deletion
strains (Jensen et al., 1996b). This assay (Fig. 1 D) demon-
strated that GFP chimera of human topo II
 
 
 
 and II
 
 
 
 were
fully capable of supporting the mitotic growth of 
 
 
 
top2
 
yeast upon eradication of the endogenous salvage plasmid
encoding 
 
Schizosaccharomyces pombe
 
 topo II (
 
 
 
5-fluoro-
orotic acid [FOA]), whereas cell growth was abolished in the
absence of an additional topo II construct. Apparently, com-
plementation by GFP chimera was as good as by untagged
topo II. Thus, the functionality of human topo II is fully
preserved in the corresponding GFP chimera.
Finally, we considered that fusion to GFP might disrupt
cellular targeting of topo II. Therefore, we compared the dis-
tribution patterns of endogenous and GFP-tagged topo II by
indirect immunofluorescence. Fig. 1 E shows examples of mi-
totic and of interphase cells labeled with isozyme-specific topo
II antibodies. Untransfected cells (Fig. 1 E, top panels) gave
rise to antibody-derived signals only, whereas cells expressing
topo II
 
 
 
–GFP (Fig. 1 D, bottom left) or topo II
 
 
 
–GFP (Fig.
1 E, bottom right) also emitted GFP fluorescence. The distri-
bution patterns of GFP fluorescence (specific for GFP fusion
proteins only) and immunofluorescence (specific for fused
and endogenous enzymes) were virtually identical, attesting to
the fact that the GFP chimera colocalized with their endoge-
nous counterparts. In addition, distribution patterns of topo
II in nontransfected and in topo II–GFP-expressing cells were
identical (Fig. 1 D, compare top and bottom portion), mak-
ing it unlikely that the GFP chimera disrupted localization of
the endogenous enzymes. It should be noted that the patterns
shown in Fig. 1 E do not represent the true localization of
topo II
 
 
 
 or II
 
 
 
 in living cells, because these cells were fixed
and permeabilized which is known to alter the cellular distri-
 
Figure 4.
 
Features of topo II isoforms in mitosis.
 
 (A) Centromeric 
accumulation of topo II
 
 
 
 at metaphase is lost upon transition to 
anaphase. Topo II
 
 
 
–GFP-expressing cells were grown on cover 
slides, then flattened by placing the slide with adherent cells 
directly onto a glass slide, and imaged directly thereafter. Represen-
tative examples of cells at metaphase (left) and anaphase (right) 
are presented by phase contrast (top) and corresponding green 
fluorescence of GFP (bottom). Arrowheads indicate an example of 
centromeric accumulation of topo II
 
 
 
, as characterized by two pairs 
of dots per chromosome. (B) Topo II  is not excluded from mitotic 
chromosomes. A single high-resolution, confocal section of 
metaphase cells expressing either GFP alone (left) or topo II –GFP 
(right) is shown (inserts: images of transmitted light of the same 
cells). (C) Topo II  and topo II  accumulate on mitotic chromo-
somes upon treatment with VM 26. Cells expressing topo II –GFP 
(top) and II –GFP (bottom) were imaged by confocal microscopy 
before (0 min) and at the indicated time points after the addition 
of 100  M VM 26.36 The Journal of Cell Biology | Volume 157, Number 1, 2002
Figure 5. FRAP analysis of topo II–GFP. Cells expressing GFP chimera of topo II  and II  were bleached for 1.8 s. Images were taken before 
bleaching and at the indicated time points after the end of the bleach pulse. The area to be bleached is indicated by a circle in the prebleach 
panels. In VM 26–treated cells a nucleolar or a nucleoplasmic region was bleached simultaneously in the same cell, whereas in untreated Dynamics of human topo II  and II  in living cells | Christensen et al. 37
bution of topo II in an unpredictable fashion (Chaly and
Brown, 1996). In fact, when we applied different protocols
for permeabilization and/or fixation, we also obtained pat-
terns different from those shown in Fig. 1 E, but in each case
antibody staining and GFP fluorescence were identical. The
colocalization of topo II and GFP epitopes in fixed cells shows
that the cellular targeting of topo II–GFP chimera is similar to
that of the endogenous enzymes. Thus, the GFP-tagged en-
zymes should also reflect faithfully the localization of topo II
in living cells.
Distribution of topo II  and II  in living cells
Monitoring of topo II –GFP and topo II –GFP in living
cells by GFP fluorescence revealed a very similar distribution
of the isozymes in interphase nuclei (Fig. 2): both were ex-
clusively in the nucleus, where they resided in the nucleo-
plasm and the nucleoli. The minor, nucleoplasmic subpopu-
lation had a slightly uneven distribution. The major fraction
of both isoforms accumulated in the nucleoli. It had a
cloudy but otherwise unstructured distribution in the entire
nucleolar space which distinctively excluded small globular
compartments (not yet identified), imposing as dark holes
within the brightly fluorescent nucleolus (Fig. 2, insert, ar-
rows).
During cell division, the localization of topo II isoforms
differed markedly. Fig. 3 shows time-lapsed images of topo
II –GFP (left) and topo II –GFP (right) in cells pro-
ceeding from metaphase (0 ) to early G1-phase (90 )
(Video 1, available at http://www.jcb.org/cgi/content/full/
jcb.200112023/DC1, showing cell cycle progression from
prophase through G1-phase acquired by confocal micros-
copy). Topo II –GFP was mostly chromosome-associated
from metaphase until telophase (0–10 min). Chromosomal
structures were distinctively labeled by the enzyme, whereas
the mitotic cytosol contained only a minor fraction. In con-
trast, association of topo II –GFP with chromosomes varied
during mitosis. In metaphase (0 min), the enzyme was
mostly in the cytosol; it started to associate with the chro-
mosomes as soon as they were segregated (4 min) and con-
tinued to accumulate there until cytokinesis (18 min). From
then on and throughout interphase, the two isoforms be-
haved similarly. During nuclear reorganization in early G1-
phase (18–90 min), they concentrated in small, light–dense
structures (18 and 28 min) which later on (45 and 90 min)
gradually assembled into nucleoli. It is interesting to note
that the patterns at early G1-phase (e.g., 28 min) resemble
those of established marker proteins of prenucleolar bodies
(e.g., B23; Olson et al., 2000), suggesting that both topo II
isozymes participate in postmitotic reassembly of nucleoli.
Because of the dense chromosome packing, we could not
resolve the subchromosomal localization of topo II  in
metaphase plates of living cells. To overcome the problem,
metaphase chromosomes were spread out by gentle mechan-
ical compression of the cells (Fig. 4 A) which revealed a cen-
tromeric accumulation of topo II –GFP (Fig. 4 A, left).
However, in anaphase the enzyme appeared to be evenly dis-
tributed over the whole chromosome (Fig. 4 A, right). These
observations are in good agreement with previous immuno-
histochemical findings (Taagepera et al., 1993; Rattner et
al., 1996; Sumner, 1996), supporting the idea that in
metaphase (at the onset of chromatid segregation), topo II 
has its major role in separating the last catenates of centro-
meric DNA. It is interesting to see here how fast the enzyme
becomes subsequently redistributed within the chromo-
some, considering the rapid progression of cells from
metaphase to anaphase (Fig. 3 and Video 1, available at http:
//www.jcb.org/cgi/content/full/jcb.200112023/DC1).
The data in Fig. 3 show that topo II  does not accumu-
late on chromosomes before telophase. This could either
mean that the enzyme is altogether excluded from the con-
densing chromatin, or that a large cytoplasmic pool of topo
II  obscures a smaller, chromosome-associated fraction. Ev-
idence for the latter assumption came from a comparison of
GFP alone and topo II –GFP by high-resolution confocal
microscopy of metaphase cells (Fig. 4 B). The untagged,
freely diffusible protein GFP was clearly excluded from
densely packed metaphase chromosomes (Fig. 4 B, left),
whereas this was not the case for topo II –GFP (Fig. 4 B,
right). Here, the metaphase plate exhibited the same fluores-
cence intensity as the surrounding cytosol and was even
highlighted by more intense speckles. This pattern argues
against an exclusion of topo II  from metaphase chromo-
somes. It suggests that a minor fraction of the enzyme is in-
deed chromosome-associated at this stage of mitosis.
Further evidence for this hypothesis was obtained from
metaphase cells treated with the topo II–specific drug VM
26 (Fig. 4 C). This caused a rapid redistribution of both
topo II –GFP (Fig. 4 C, top) and topo II –GFP (bottom)
from the cytosol to the chromosomes, indicating that the
drug efficiently trapped both isozymes on chromosomal
DNA. Of interest, the VM 26–induced chromosomal accu-
mulation of topo II –GFP was faster and more complete
than that of topo II –GFP. In summary, these data indicate
that during mitosis topo II  has a propensity to engage in
DNA turnover, but the enzyme is clearly biased to the cyto-
solic state. In addition, the rapid redistribution of both iso-
forms from the cytosol to the chromosomes after treatment
with VM 26 suggests a dynamic interchange between the
two populations thus identifying these enzymes as highly
mobile constituents of the mitotic cell.
Mobility of topo II  and II  and the effects 
of topo II poisons
To follow up on the mobility of topo II  and topo II  in
living cells, we employed photobleaching techniques. Fig. 5
summarizes a series of experiments, determining the mobil-
ity of topo II  and II  in interphase nuclei via kinetics of
FRAP (White and Stelzer, 1999). Topo II–linked GFP fluo-
rescence was bleached irreversibly in circular areas (Ø   1
 m) by high-powered laser pulses and fluorescence recovery
cells each compartment was bleached in separate cells. Corresponding quantitative data of fluorescence recovery kinetics are plotted below. 
Fluorescence intensities in the bleached region were measured and expressed as the relative recovery over time. Values represent means from 
at least six individual cells and three independent experiments. Standard deviations were in each case  5% of the mean values (unpublished 
data). FRAP kinetics of freely diffusible GFP, chromatin-bound histone H3-GFP and formaldehyde-fixed topo II –GFP served as controls.38 The Journal of Cell Biology | Volume 157, Number 1, 2002
Figure 6. Exchange between nucleoplasmic and nucleolar 
topo II–GFP. Cells expressing GFP chimera of topo II , II , and 
histone H3, respectively, were bleached and analyzed as in Fig. 
5 with two exceptions: (a) A larger area (3  m diam; white circle) 
was bleached to achieve a substantial loss of total cellular 
fluorescence. (b) The relative recovery over time in the bleach 
spot and the relative loss of fluorescence intensity in unbleached 
areas (black and white circles) is plotted below each image 
panel. Plotted data were not corrected for the overall loss of
fluorescence induced by the bleach pulse ( 20%), to allow a 
quantitative comparison of signal loss in unbleached areas with 
signal gain in the bleached area. For greater clarity, only every 
tenth data point is marked by a symbol.
in the bleached spots as a consequence of topo II–GFP mol-
ecules moving in from unbleached areas was recorded over
time. It is readily apparent from time-lapsed fluorescent im-
ages (Fig. 5, top) and quantitative plots of recovery kinetics
(Fig. 5, bottom) that FRAP of a nucleoplasmic or a nucle-
olar area was in each compartment fast and complete for
both topo II isoforms. This suggests that immobile mole-
cules are virtually absent. Recovery kinetics of topo II–GFP
were much faster than those of GFP-histone H3, a member
of nucleosomal core proteins (Fig. 5, Ctrls.) known to be
firmly immobilized on chromatin (Phair and Misteli, 2000).
On the other hand, both topo II isozymes were by no means
as freely diffusible as unfused GFP which exhibited recovery
kinetics even too fast to be recorded with our experimental
settings (Fig. 5, Ctrls.). Moreover, recovery of topo II –
GFP and topo II –GFP was notably slower in nucleoli
(t1/2   6.2 and 10 s, respectively) than in the nucleoplasm
(t1/2   1.8 and 3 s, respectively), suggesting less mobile en-
zyme subpopulations in the nucleoli. This, and the slight
difference in mobility between the isozymes (topo II  was
somewhat slower), raised the question of what controls topo
II mobility and which role DNA interactions play in this re-
spect. We could address this issue experimentally, as cova-
lent topo II·DNA intermediates are stabilized by specific
agents such as VM 26 (compare Figs. 1 C and 4 C). VM 26
treatment induced a profound redistribution of topo II in
the nucleus which was similar for both isoforms (Fig. 5, top
panels, bottom rows). Nucleoli became largely depleted, and
almost the entire enzyme pool concentrated at distinct sites
in the nucleoplasm, forming there a granular pattern. FRAP
analysis revealed that topo II was clearly much less mobile at
these granular nucleoplasmic sites. Notably, immobilization
was less pronounced for topo II  which still exhibited a
slight ascension of the recovery curve, whereas topo II  did
not. This is in agreement with previous pharmacological
studies showing that topo II  is less sensitive to VM 26
(Drake et al., 1989). In comparison, the small amount of
topo II  and   remaining inside nucleoli after VM 26 treat-
ment retained a much higher mobility and, here again, topo
II  was more mobile (less affected by VM 26) than topo
II . These data demonstrate for the first time directly that
the vast majority of topo II  and II  molecules present in a
living cell becomes indeed trapped by VM 26 in its co-
valently DNA-bound intermediate state which must be re-
lieving for oncologists, relying on this mechanism of action
for tumor therapy. These findings also suggest that nuclear
sites where topo II normally accumulates (Fig. 2) do not
necessarily represent sites where the enzymes are most ac-
tively engaged in DNA catalysis. This is most evident in nu-
cleoli where topo II concentration is highest (Fig. 2), en-
zyme mobility is lowest (Fig. 5, untreated cells), but
entrapment by VM 26 is least efficient (Fig. 5, VM 26-
treated cells). Thus, interaction of topo II with genomic
DNA seems not to constitute the major determinant of topo
II localization or mobility.
To investigate whether all topo II–GFP molecules are free
to traffic between different nucleoli and between nucleoli
and the nucleoplasm, we applied a combined FRAP/fluores-
cence loss in photobleaching (FLIP) analysis (Fig. 6). First,
an entire nucleolus was bleached in a circular area (Ø   3Dynamics of human topo II  and II  in living cells | Christensen et al. 39
of a chromosomal area in a metaphase plate, was fast (t1/2  
3.5 s) and complete. We obtained similar recovery kinetics
with chromosomes of cells in pro-, ana- or telophase (un-
published data). Moreover, the FLIP experiment shown in
Fig. 8 B demonstrates that all topo II –GFP fluorescence
was lost from chromosomes and the cytoplasm of a given
cell when repeated bleach pulses were applied to a distinct
chromosomal area. Comparable results were obtained when
the cytosol was repeatedly bleached (unpublished data). In
summary, these data indicate that topo II  is mobile within
the chromosome. An immobile fraction is virtually absent.
The FLIP experiment also demonstrates unrestricted move-
ments of the enzyme between chromosomes and the cyto-
plasm. To corroborate these controversial findings, we
needed to prove that we would have detected an immobile
fraction, if present. This was achieved in two ways. First, we
demonstrated immobility of GFP-histone H3 in mitotic
chromosomes (Fig. 8 A, bottom). Second, we demonstrated
immobility of topo II –GFP and topo II –GFP trapped on
 m). Subsequently, we recorded by sequential imaging
scans the fluorescence recovery of the bleached nucleolus
and the loss of signal intensity in an unbleached nucleolus of
the same cell and in a neighboring, unbleached nucleoplas-
mic area. To enable a comparison of FRAP and of FLIP,
quantitative data were plotted without the usually applied
correction for the bleach pulse-induced, overall loss of fluo-
rescence, giving rise to the slightly unusual drawings shown
in Fig. 6. The plots for topo II –GFP (Fig. 6, top) and topo
II –GFP (Fig. 6, middle) show that in both cases the fluo-
rescence of the bleached nucleolus recovered at the expense
of the two neighboring areas which decreased by the same
rate. The three curves rapidly reached equilibrium, and the
equilibrium values were virtually the same, indicating that
the mean fluorescence intensity of nucleoli, having com-
pletely recovered from bleaching, was identical to un-
bleached ones which lost a corresponding amount of fluo-
rescence over time. Moreover, unbleached nucleoli were
subjected to the same percentage loss of fluorescence inten-
sity as the nucleoplasm. Thus, bleached topo II molecules
(from the bleach spot) and unbleached ones (from the se-
lected neighboring areas) mixed completely within the time
frame of the experiment, indicating that all of them could
freely move between their respective nuclear compartments.
These data are in striking contrast to those obtained with the
largely immobile GFP-histone H3 (Fig. 6, bottom), where
fluorescence recovery in the bleach spot and fluorescence
loss in the neighborhood did not converge.
The free exchange of topo II between nuclear compart-
ments was further corroborated by a conventional FLIP ex-
periment (White and Stelzer, 1999), where nucleoli labeled
by topo II –GFP or topo II –GFP were repeatedly
bleached (Fig. 7). As a consequence, all topo II–GFP fluo-
rescence was lost from the nucleoplasm as well as from other
nucleoli, indicating that all fluorescent topo II molecules
were eventually hit by a bleach pulse and therefore must be
exchanging rapidly between the nuclear subcompartments.
In summary, these data support the conclusion of a rapid
and unrestricted exchange of fluorescent topo II molecules
between individual nucleoli, and between the nucleoplasm
and nucleoli. This interpretation is more in agreement with
a recent concept proposing rapid and continuous diffusional
movement of proteins between nucleoplasm and nuclear
compartments (Misteli, 2001) than with the older idea of
distinct subpopulations of topo II existing in separate cellu-
lar pools (Swedlow et al., 1993).
Mobility of mitotic topo II 
The high degree of mobility of topo II  and II  in inter-
phase nuclei makes it unlikely that the enzymes play a struc-
tural role in building a karyoskeleton. However, it is still
possible that they participate in building the mitotic chro-
mosome scaffold which is the major structural role proposed
for these enzymes (Adachi et al., 1991). To address this is-
sue, we determined the mobility of topo II  in chromo-
somes (Fig. 8). These experiments were restricted to the
 -isozyme, because chromosomal and cytosolic locations of
topo II –GFP could not be reliably discriminated (compare
Figs. 8 and 4 B). Unexpectedly, fluorescence recovery of
topo II –GFP (Fig. 8 A, upper panel) after photobleaching
Figure 7. FLIP analysis of interphase topo II–GFP. Nucleoli of 
cells expressing topo II –GFP or topo II –GFP were repeatedly 
bleached in a circular area (3  m diam; white circles). Cells were 
imaged before each new bleach pulse, and fluorescence intensities 
of neighboring nucleoli and nucleoplasmic areas (black and white 
circles) were determined. Almost all fluorescence was lost from 
both compartments after 50 bleach cycles, indicating a high 
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chromosomal DNA by VM 26 (Fig. 8 A, middle panels).
Both control experiments attest to the validity of our data
regarding the unexpected degree of mobility of chromo-
somal topo II  in the absence of VM 26.
Is topo II axially located in chromosomes?
Our data obviously conflict with the established view that
topo II  plays a structural role in building a static chromo-
some scaffold. This view stems in part from observations
made by indirect immunofluorescence microscopy, demon-
strating topo II along the longitudinal axes of chromosome
arms (Earnshaw and Heck, 1985; Gasser et al., 1986;
Taagepera et al., 1993; Sumner, 1996; Meyer et al., 1997).
However, such axial patterns were not seen when rho-
damine-labeled topo II was injected into living insect cells
(Swedlow et al., 1993), and were not consistently seen with
immunofluorescence (Warburton and Earnshaw, 1997).
Here, we determined the distribution of GFP-tagged topo
II  in chromosomes of living cells and in native chromo-
some spreads prepared thereof.
Fig. 9 A shows high-resolution confocal microscopy im-
ages of topo II –GFP and GFP-histone H3 in single chro-
mosomes of living cells. The quantitative analysis of fluores-
cence intensity distribution in representative cross sections
of the chromosomes (boxes) shows that both proteins cov-
ered a similar chromosome diameter of 0.8–1  m, and had
a similar distribution. Because histone H3 is an integral part
of the chromatin and hence can be assumed to cover the en-
tire chromosome, these data suggest that, in living cells, topo
II  is not confined to chromosome axes.
Next, we exposed cells at metaphase expressing topo II –
GFP (Fig. 9 B, left) or topo II –GFP (Fig. 9 B, right) to 75
mM KCl for 2 min which is a standard procedure for pre-
paring chromosome spreads. As expected, the cells increased
in volume (Fig. 9 B, top). Unexpectedly, the metaphase
plate was completely disrupted by the treatment and, most
notably, the entire cellular complement of topo II  and II 
became associated with the chromosomes (Fig. 9 B, bot-
tom). This redistribution closely resembles the effect of VM
26 (compare Figs. 9 B and 4 C), suggesting that hypotonic
treatment disrupts the catalytic cycle of topo II in such a way
that all enzyme molecules are rapidly (within 2 min) trapped
in the DNA-bound state. Fig. 9 C shows chromosome
spreads subsequently prepared from swollen cells spotted on
microscope glass slides and mounted without further fixa-
tion. When such native chromosomes were inspected imme-
diately after spreading (Fig. 9 C, top), both GFP-tagged
topo II isoforms (GFP) appeared to be more or less evenly
distributed over the whole length and width of the chromo-
some arms, as defined by the DNA stain (DAPI). Topo II –
GFP was enhanced at the centromeres (arrows), whereas this
was less evident for topo II –GFP. When the same speci-
men were inspected after incubation at ambient temperature
for 2 h (Fig. 9 C, bottom), the overall intensity of topo II–
GFP-specific signals decreased and the pattern changed.
Both isoforms were now clearly confined to the central axis
of chromosome arms, delineating a structured pattern that
closely resembled numerous published immunohistochemi-
cal images. In addition, centromeric accumulation became
more pronounced and evident with topo II –GFP, too.
Figure 8. Photobleaching experiments on mitotic chromosomes. 
(A) FRAP (as described in Fig. 5) of metaphase chromosomes in cells 
expressing GFP chimera of topo II  (with and without 100  M VM 
26), topo II  (VM 26-treated) or histone H3 after bleaching a circular 
area of 3  m diam. Bleaching of topo II –GFP-labeled chromosomes 
not treated with VM 26 was not possible, as they were obscured by 
large amounts of cytosolic topo II –GFP (Figs. 3 and 4 B). (B) FLIP 
(as described in Fig. 7) of a chromosomal and a cytoplasmic region 
(black and white circles) after bleaching of another chromosomal 
area (white circle) in a metaphase cell expressing topo II –GFP.Dynamics of human topo II  and II  in living cells | Christensen et al. 41
In summary, these observations demonstrate that the lo-
calization of topo II in chromosome spreads differs notably
from the situation in living cells. Apparently, hypotonic
treatment of cells triggers a series of events eventually gener-
ating an axial pattern of topo II. First, the whole comple-
ment of the enzymes relocates rapidly from the cytosol to
the chromosomes. Then, a loosely bound fraction of topo II
is gradually lost over time from the outer region of the chro-
mosome arms. This unveils another fraction bound to the
centromere and the chromosomal core in a more stable
manner. We envisage that during immunohistochemical
staining procedures topo II can easily be lost from the chro-
mosomal periphery, thus leading to the impression that topo
II is confined to the chromosome axis. This would also ex-
plain why in some cases both patterns—axial and even dis-
tribution over chromosome arms—have been detected
within the same sample (Sumner, 1996).
Discussion
Our findings about the dynamic distribution and mobility
of topo II isoforms in living cells have implications for their
involvement in nuclear architecture. Recent studies using
photobleaching techniques have shown that only a few com-
ponents of the nucleus are immobile, i.e. the chromatin it-
self, chromatin-bound core histones (Phair and Misteli,
2000), and structural components building the nuclear lam-
ina (Moir et al., 2000), whereas most other nuclear proteins
move rapidly throughout the nucleus. Moreover, the com-
ponents of nuclear compartments, e.g. nucleoli, seem to be
in continuous flux between the compartment and the nu-
cleoplasm (Misteli, 2001). Here, we find that both human
topo II isoforms belong to the class of mobile proteins.
Their entire pools are mobile and exchange rapidly between
nuclear compartments in interphase and between chromo-
somes and the cytoplasm in mitosis. This came as a surprise,
considering the general opinion on the dual role of topo II as
an enzyme and a structural protein forming a mitotic scaf-
fold or interphase nuclear matrix (Berrios et al., 1985; Earn-
shaw and Heck, 1985; Gasser et al., 1986; Adachi et al.,
1991). Our observation that at each stage of the cell cycle
bleached areas were rapidly and completely replenished with
fluorescent topo II molecules, makes it unlikely that even a
subpopulation of topo II could be an integral component of
immobile structures such as a putative karyoskeleton or
chromosome scaffold. However, we cannot rule out that
topo II transiently associates with such structures. In fact,
the often reported colocalization of topo II with the chro-
mosomal core together with our own observations on the
distribution of topo II–GFP in native chromosome spreads
(Fig. 9 C) even suggests a tight (but dynamic) interaction of
topo II with the chromosomal scaffold.
On the other hand, topo II is obviously restricted in its
mobility, because it moves slower than GFP which is be-
lieved to be freely diffusible. It has been proposed that such
an attenuation in mobility is caused by interactions with less
mobile nuclear components (Misteli, 2001). However, the
nature of such components—the chromatin, a putative karyo-
skeleton, or both—is an unsolved issue (Shopland and
Lawrence, 2000; Misteli, 2001). In this respect, our observa-
tion that VM 26 treatment depletes topo II from nucleoli is
of interest, because it suggests that it is not the direct interac-
tion with chromatin that slows down topo II and causes its
accumulation in this compartment. Moreover, nucleoli re-
cruit most of the topo II complement of the nucleus and it is
not likely that such a large fraction is required for the topo-
logical organization of the nucleolar chromatin which is
Figure 9. Chromosomal distribution of topo II. (A) Single chromo-
somes in living metaphase cells expressing topo II –GFP or GFP-
histone H3 were imaged by high resolution confocal microscopy. 
Distribution of fluorescence intensity was quantified in the boxed 
cross sections of the chromosomes. Mean fluorescence intensity of 
pixel columns across the short diameter of the boxes was normal-
ized to maximal values, and plotted against corresponding distances 
measured across the long diameter of the boxes (right). (B) Effect of 
hypotonic treatment on topo II distribution in metaphase. Two cells 
expressing topo II –GFP or topo II –GFP were imaged by confocal 
microscopy before (0 min) and 2 min after exchanging the medium 
for KCl solution (75 mM). Images of transmitted light are shown 
above a corresponding confocal section showing green fluores-
cence of the same cell. Note the substantial increase in size of
KCl-treated cells. (C) Subchromosomal distribution and stability of 
topo II isoforms in unfixed, spread chromosomes. Cells expressing 
topo II –GFP or topo II –GFP were harvested, collected by centrif-
ugation, swollen in hypotonic solution, and spotted on glass slides 
without fixation. Spread chromosomes were mounted in DAPI-
containing CSK buffer and imaged either immediately (top) or 2 h 
later (bottom) using filter sets for the specific detection of the DNA 
stain (DAPI) and the green fluorescence (GFP), respectively. Arrow-
heads mark the position of centromere pairs.42 The Journal of Cell Biology | Volume 157, Number 1, 2002
small in comparison to the entire genome. Thus, the de-
creased mobility of topo II  and II  in nucleoli is likely due
to interactions with other proteins and not with DNA. On
the other hand, considering the dense packing of topo II 
and II  in the nucleoli of living cells (Fig. 2), and consider-
ing that among numerous topo II–interacting proteins de-
scribed in the literature, none is a nucleolar protein, it could
also be imagined that polymerization of topo II (Vassetzky et
al., 1994) might create a transient, less mobile structure thus
contributing to accumulation of the enzymes in nucleoli.
Our observations also shed some light on ongoing discus-
sions about isoform-specific topo II functions in mammalian
cells. It is clear that topo II function in general is required for
maintenance of the nucleolar structure and the folding of
rDNA into functionally organized nucleolar genes in yeast and
mammals (Christman et al., 1988; Hirano et al., 1989; Iarovaia
et al., 1995). We find that both isoforms accumulate in nucleoli
and exhibit the same subnucleolar distribution, indicating that
they are both engaged in these functions. Thus, topo II  and
II  have probably many similar functions in the interphase nu-
cleus. However, our data clearly indicate that topo II  differs
significantly from topo II  in its contribution to the mitotic cy-
cle. We find that in metaphase topo II  is scarcely chromo-
some-associated. This fits with the recent observation that dis-
ruption of the TOP2  gene has little effect on early embryonal
development in mouse (Yang et al., 2000), and with our previ-
ous finding that in a mammalian cell, topo II  cannot substi-
tute topo II  during mitosis (Grue et al., 1998). It now seems
quite clear that topo II  is not required for mitotic cell division;
however, in a living cell, topo II  is not fully excluded from
metaphase chromosomes (Fig. 4 B), and to some extent it re-
tains the ability to engage in catalytic DNA turnover in the
chromosome (Fig. 4 C). This might be sufficient to support mi-
totic topo II functions in yeast (Jensen et al., 1996a; Fig. 1 C),
but not in mammals (Grue et al., 1998).
Materials and methods
Plasmid construction
Bicistronic expression vectors for mammalian cells were constructed from
the plasmid pMC-2P (Mielke et al., 2000), in which the translational initia-
tion of the selection marker in the second cistron is mediated by an inter-
nal ribosome entry site from poliovirus. The coding sequences for GFP and
for fusions of human topo II isoforms and GFP were inserted in front of the
internal ribosome entry site by linker PCR. For the yeast complementation
assay plasmids pHT300 and pHT400 (Jensen et al., 1996a), carrying
cDNAs of human topo II  and II  under the control of the yeast triose
phosphate isomerase (TPI) gene promoter, were modified to express hu-
man topo II–GFP fusion proteins by replacing 3 -terminal restriction frag-
ments of topo II reading frames by PCR-generated fragments containing the
respective GFP chimera from the mammalian expression vectors.
Cell culture and transfection
The human embryonal kidney cell line 293 (DSMZ) was grown at 37 C in
a humidified atmosphere of 5% CO2 in DME with Glutamax-I (GIBCO
BRL) supplemented with 10% fetal bovine serum, 100 U penicillin/ml, and
100   g ml
 1 streptomycin. Cells were transfected using Lipofectamine
(GIBCO BRL) according to the manufacturer’s instructions. After 2 d, stable
cell lines were selected and maintained thereafter in medium containing
0.35  g ml
 1 puromycin.
Complementation assay
Yeast complementation was carried out as described by Jensen and col-
leagues (1996a). Briefly, LEU2 expression plasmids for human topo II iso-
forms and the respective GFP chimera were transformed into the haploid
 top2 strain BJ201 (pHT173 [S.pombe TOP2/URA-ARS/CEN] MAT  ura3
trp1 leu2 his3 pep4::HIS3 prb1Dcan1 top2::TRP1 GAL) which contains a
URA3 plasmid carrying the S. pombe TOP2 gene to substitute for the es-
sential topo II activity. Colonies from selection plates (without Leu) were
then streaked onto media containing 1 mg ml
–1 5-FOA to counterselect
against the plasmid carrying the S. pombe TOP2 gene.
Immunoblotting and band depletion assay
5   10
5 cells were harvested, resuspended in PBS, and lysed by addition of
an equal volume of twofold lysis buffer (250 mM Tris-HCl, pH 6.8, 10%
SDS, 8 M urea, 20% glycerol, 0.04% bromophenol blue, 10 mM 4-[2-
Aminoethyl]-benzenesulfonyl fluoride, 1 mM PMSF, 20  g ml
 1 Aprotinin,
10  g ml
 1 Pepstatin A). Whole cell lysates were separated by SDS-PAGE,
and blotted onto PVDF membranes (Immobilon P; Millipore). Blots were
blocked in 2% BSA, 0.05% Tween 20 in CMF-PBS (167 mM NaCl, 25.5
mM Na2HPO4, 2 mM KH2PO4, pH 7.5) and then incubated for 1 h in the
same buffer with diluted primary antibodies (mouse monoclonal topo II 
antibody KiS1 [Boege et al., 1995]; mouse monoclonal peptide topo II 
antibody 3H10 [Kimura et al., 1996]; mouse monoclonal GFP-antibody
[CLONTECH Laboratories, Inc.]; and mouse monoclonal  -tubulin anti-
body [Sigma-Aldrich]). After washing, the filters were incubated with HRP-
conjugated goat anti–rabbit or goat anti–mouse antibodies in 2% BSA,
0.1% Tween 20 in CMF-PBS for 1 h. After extensive washing with the
same buffer, specific protein bands were detected with the ECL Plus system
(Amersham Pharmacia Biotech). For immunoband depletion, cells were
incubated with 200  M VM 26 for 1 h prior to harvesting.
Immunoprecipitation and kDNA decatenation
Magnetic particles (Dynabeads M 500; Dynal) were covalently coated (ac-
cording to the producers manual) with rabbit antibodies against topo-
isomerase II  (Genosys) and mouse monoclonal antibodies against topo II 
(Meyer et al., 1997) or GFP (Roche). 2   10
7 coated beads were saturated
for 2 h at 4 C with nuclear extracts obtained from 10
9 cells (Meyer et al.,
1997). Subsequently, the beads were collected with a magnet, washed
with binding buffer (175 mM NaCl, 6 mM Hepes, pH 7.5, 2 mM EDTA,
14% glycerol, 0.2 mM DTT, 0.5 mM 4-[2-Aminoethyl]-benzenesulfonyl
fluoride, 10  g ml
 1 aprotinin, 5% FBS), and then with assay buffer (120
mM KCl, 50 mM Tris HCl, pH 7.9, 10 mM MgCl2, 1 mM ATP, 0.5 mM
DTT, 0.5 mM EDTA, 30  g ml
 1 BSA). Finally, the beads were incubated
for 2 h at 37 C with 1  g crithidia fasciculata kinetoplast DNA (kDNA; To-
poGen, Inc.) in a final volume of 40  l assay buffer. Negative controls in-
cluded addition of 300  M Na3VO4 and beads not incubated with nuclear
extracts. Alternatively, the beads were eluted with 100 mM Na3PO4, 100
mM NaCitrate, pH 3 and 3 M urea. Eluates were subjected to SDS-PAGE
(6% gels) and visualized by silver staining.
Immunocytochemistry
Cells were grown on microscopic coverslips, washed in PBS, fixed in 2%
paraformaldehyde in PBS for 15 min on ice, and permeabilized with
0.25% Triton X-100 in the presence of 1% paraformaldehyde in PBS for 10
min on ice. All subsequent steps were carried out at ambient temperature.
After washing with PBS, cells were blocked for 1 h in PBS, 2% BSA, 5%
goat serum and then incubated for 1 h with topo II  antibody KiS1 or topo
II  antibody 3H10 diluted 1:500 in blocking solution. After washing,
bound antibodies were visualized by incubation for 1 h with Cy3™-conju-
gated goat anti–rabbit or anti–mouse F(ab )2 fragments (Dianova) diluted
1:1,000. Coverslips were then washed three times for 5 min in PBS. The
first wash contained 80 ng ml
 1 DAPI to stain genomic DNA.
Microscopy
Epifluorescent images were acquired with appropriate filter sets (AHF
Analysentechnik) at 630  magnification using an inverted microscope
(Axiovert 100; Carl Zeiss) equipped with a cooled charge-coupled device
camera (Sensys; Photometrics Ltd.) and an additional 4  magnification
lens. Living cells were grown and inspected in CO2-independent medium
(GIBCO BRL) in poly-L-lysine–coated live-cell chambers (Bioptechs, Inc.)
at 37 C.
Confocal imaging, FRAP and FLIP analyses of living cells were per-
formed at 37 C with a Zeiss LSM 510 inverted confocal laser scanning mi-
croscope equipped with a CO2-controlled on-stage heating chamber using
a heated 63 /1.4 NA oil-immersion objective and the FITC filter setting
(488 nm/ 515 nm). It should be emphasized that strict temperature control
was crucial for topo II localization and mobility. For FRAP experiments, a
single optical section was acquired with 5.6  zoom. Images were taken
before and at 1.577 s time intervals after bleaching of a circular area at 20Dynamics of human topo II  and II  in living cells | Christensen et al. 43
mW nominal laser power with three iterations. The imaging scans were
aquired with a laser power attenuated to 0.1–1% of the bleach intensity.
The same settings were used for FLIP experiments where cells were repeat-
edly bleached and imaged at intervals of 15 s. For quantitative FRAP anal-
ysis, fluorescence intensities of the bleached region and the entire cell nu-
cleus were measured at each time point. Data were corrected for
extracellular background intensity and for the overall loss in total intensity
as a result of the bleach pulse itself and the imaging scans. Unless stated
otherwise, FRAP recovery curves were generated by calculating the rela-
tive intensity of the bleached area Irel as described (Phair and Misteli,
2000). FLIP depletion curves of selected areas outside the bleach spot were
just corrected for the loss of fluorescence intensity caused by the imaging
scans by comparison with the fluorescence intensity of a neighboring cell
nucleus. Bleaching of mitotic cells (Fig. 8) was performed in the presence
of 0.1  M paclitaxel to reduce movements of the chromosomes.
Spreading of native chromosomes
10
7 exponentially growing cells were harvested, collected by centrifuga-
tion for 5 min at 160 g, and carefully resuspended in 6 ml hypotonic solu-
tion (0.075 M KCl). Cells were pelleted as above, resuspended in 400  l
hypotonic solution and drops of about 50  l were then spotted on a
slightly tilted glass slide. Prior to this, slides were carefully cleaned in
methanol and then soaked in double distilled water. After spreading, unat-
tached cells were removed by letting 200  l isotonic cytoskeleton CSK
buffer (100 mM KCl, 300 mM sucrose, 10 mM Pipes, pH 6.8, 3 mM
MgCl2, 1 mM EGTA, 10 mM 4-[2-Aminoethyl]-benzenesulfonyl fluoride, 1
mM PMSF, 20  g/ml Aprotinin, 10  g/ml Pepstatin A) containing 80 ng/ml
DAPI run down the slightly tilted slide. Spread chromosomes were then
carefully mounted in the same buffer.
Online supplemental material
Video 1 (available at http://www.jcb.org/cgi/content/full/jcb.200112023/
DC1)(10 images per second) shows topo II –GFP- and topo II –GFP-
expressing cells proceeding through a mitotic cycle from prophase to early
G1 phase. Time-lapsed images (one image every 30 s) were acquired by
confocal microscopy, and corresponding images of transmitted light (left)
and green fluorescence (right) are mounted side by side.
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